An Overlooked Generic Drug Pathway: 505(b)(2)
07/19/2019
Category: Regulatory
Traditionally the generic drug makers submitted Abbreviated New Drug Applications (ANDA), however more have been opting for the 505(b)(2) regulatory pathway. The...
Read More